FUNDAMENTALS · Fundamentals · US Healthcare

Vir Biotechnology (VIR) Fundamentals 2026 — Revenue Analysis | SniperIQ

Vir Biotechnology (VIR) is a US-listed Healthcare company in Biotechnology with a market capitalization of

.6B, trading at $9.31 on the NASDAQ. This SniperIQ fundamentals page covers Vir Biotechnology's valuation, profitability (net margin -676.0%), revenue ($69M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.6B
Net Margin-676.0%
Revenue (FY25)$69M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Vir Biotechnology's market cap?

Vir Biotechnology (VIR) has a market capitalization of approximately

.6B, trading at $9.31 on the NASDAQ. Market cap moves with the live share price.

What is Vir Biotechnology's P/E ratio?

Vir Biotechnology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Vir Biotechnology?

Vir Biotechnology runs a net profit margin of -676.0%, a gross margin of 275.2%, and an operating margin of -704.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Vir Biotechnology generate?

Vir Biotechnology reported revenue of $69M for fiscal year 2025, with net income of -$438M and earnings per share (EPS) of -3.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Vir Biotechnology pay a dividend?

Vir Biotechnology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Vir Biotechnology financially healthy?

Vir Biotechnology carries a debt-to-equity ratio of 0.12x and a current ratio of 7.11x, with a market beta of 1.62. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Vir Biotechnology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Vir Biotechnology (VIR) the key facts are: market cap

.6B, revenue $69M, 52-week range 4.155-11.66. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Vir Biotechnology's full fundamentals live

Get Vir Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Innoviva (INVA) fundamentals · Maze Therapeutics (MAZE) fundamentals · MoonLake Immunotherapeutics (MLTX) fundamentals · Biohaven (BHVN) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons